Severe nonalcoholic steatohepatitis and type 2 diabetes: liver histology after weight loss therapy in a randomized clinical trial
- PMID: 30431378
- DOI: 10.1080/03007995.2018.1547696
Severe nonalcoholic steatohepatitis and type 2 diabetes: liver histology after weight loss therapy in a randomized clinical trial
Abstract
Objective: To evaluate the effectiveness of the fast weight loss method on liver steatosis, fibrosis, inflammation, glycemic and lipid features and body composition in patients with severe nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2D).
Methods: A 24 week open prospective randomized controlled clinical trial including 80 adult patients (aged 40-65 years) was performed. The patients after randomization were divided into two groups: the main group followed the fast weight loss method; the control group received conventional drug treatment. The fast weight loss method included calorie restriction, salt intake, walking and sexual self-restraint. The conventional drug therapy included vitamin E, orlistat, pioglitazone hydrochloride, atorvastatin, lisinopril, benzodiazepines and anti-inflammatory agents. Primary endpoints were: ultrasound and histology suggestive of steatohepatitis, hepatic enzymes, weight loss, 2 hour oral glucose tolerance test and glycosylated hemoglobin A1C (HbA1c). Secondary endpoints were: blood pressure and lipids.
Results: A total of 83% patients completed the study. In the main group weight lost was 7-16 kg (10-20% from baseline) for 8-10 weeks. In this group weight was lost due to reduction of fat mass only. The main vs. control group showed higher decrease in fat mass from baseline (p < .001). Ultrasound imaging and liver histological scoring system evidenced significant improvement in liver steatosis/fibrosis in the main group (p < .001). In the main vs. control group weight lost at 24 weeks led to positive laboratory changes in alanine aminotransferase (ALT), aspartate aminotransferase (AST), 2 hour oral glucose tolerance test (OGTT), HbA1c, Homeostasis Model Assessment insulin resistance indexes (HOMA-IR), blood pressure (BP), cholesterol, triglycerides, bilirubin total and blood hemoglobin (p = .01). The fast weight loss in the patients adequately led to decrease in symptomatic drugs up to complete abolition.
Conclusions: The study showed benefits of the fast weight loss method improving in steatosis/fibrosis and biochemical/metabolic outcomes in patients with severe NASH and T2D.
Keywords: Severe nonalcoholic steatohepatitis; fast weight loss; fibrosis; type 2 diabetes.
Comment in
-
Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment.Curr Med Res Opin. 2019 Jul;35(7):1305-1306. doi: 10.1080/03007995.2019.1589152. Epub 2019 Apr 8. Curr Med Res Opin. 2019. PMID: 30819009 No abstract available.
-
Response: non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment.Curr Med Res Opin. 2019 Jul;35(7):1307-1308. doi: 10.1080/03007995.2019.1589153. Epub 2019 Apr 8. Curr Med Res Opin. 2019. PMID: 30821517 No abstract available.
Similar articles
-
Weight loss treatment for COVID-19 in patients with NCDs: a pilot prospective clinical trial.Sci Rep. 2024 May 14;14(1):10979. doi: 10.1038/s41598-024-61703-1. Sci Rep. 2024. PMID: 38744929 Free PMC article. Clinical Trial.
-
Biochemical parameters response to weight loss in patients with non-alcoholic steatohepatitis.Afr Health Sci. 2016 Mar;16(1):242-9. doi: 10.4314/ahs.v16i1.32. Afr Health Sci. 2016. PMID: 27358638 Free PMC article. Clinical Trial.
-
IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.Endocr Pract. 2020 Apr;26(4):444-453. doi: 10.4158/EP-2019-0342. Epub 2020 Jan 22. Endocr Pract. 2020. PMID: 31968197
-
Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.Expert Rev Clin Pharmacol. 2017 May;10(5):535-547. doi: 10.1080/17512433.2017.1300059. Epub 2017 Mar 6. Expert Rev Clin Pharmacol. 2017. PMID: 28276774 Review.
-
Evaluations of Lifestyle, Dietary, and Pharmacologic Treatments for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review.Clin Gastroenterol Hepatol. 2019 Jul;17(8):1457-1476.e7. doi: 10.1016/j.cgh.2018.05.023. Epub 2018 May 29. Clin Gastroenterol Hepatol. 2019. PMID: 29857146
Cited by
-
Standardised Outcome Reporting for the Nutrition Management of Complex Chronic Disease: A Rapid Review.Nutrients. 2021 Sep 26;13(10):3388. doi: 10.3390/nu13103388. Nutrients. 2021. PMID: 34684389 Free PMC article. Review.
-
Endothelium dysfunction and thrombosis in COVID-19 with type 2 diabetes.Endocrine. 2023 Oct;82(1):15-27. doi: 10.1007/s12020-023-03439-y. Epub 2023 Jul 1. Endocrine. 2023. PMID: 37392341 Review.
-
Nutritional Approaches for the Management of Nonalcoholic Fatty Liver Disease: An Evidence-Based Review.Nutrients. 2020 Dec 17;12(12):3860. doi: 10.3390/nu12123860. Nutrients. 2020. PMID: 33348700 Free PMC article. Review.
-
Atorvastatin and Vitamin E Accelerates NASH Resolution by Dietary Intervention in a Preclinical Guinea Pig Model.Nutrients. 2019 Nov 19;11(11):2834. doi: 10.3390/nu11112834. Nutrients. 2019. PMID: 31752351 Free PMC article.
-
Weight loss treatment for COVID-19 in patients with NCDs: a pilot prospective clinical trial.Sci Rep. 2024 May 14;14(1):10979. doi: 10.1038/s41598-024-61703-1. Sci Rep. 2024. PMID: 38744929 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical